The United Kingdom (UK) has issued a position paper on ensuring a smooth economic transition from the European Union (EU) in relationship to the availability of goods, including pharmaceuticals.
The United Kingdom (UK) has issued a position paper on ensuring a smooth economic transition from the European Union (EU) in relationship to the availability of goods, including pharmaceuticals.
The paper outlines the UK’s 4 guiding principles that it will bring into its Brexit negotiations:
UK pharmaceutical trade groups praised the government’s proposals; CEO of the Association of the British Pharmaceutical Industry, Virginia Acha, DPhil, said, “We welcome this paper’s pragmatic approach, which provides a constructive starting point for arrangements that aim to minimize disruption to vital safety and monitoring processes for medicines and avoid any negative impact to medicines supply. As soon as the negotiations resume, we urge the EU and UK to discuss this issue with Europe’s patients front of mind.”
As the Brexit deadline of March 2019 draws close, trade groups are also lobbying for the UK to make new investments in pharmaceuticals in order to decrease the UK’s dependency on foreign markets. The Medicines Manufacturing Industry Partnership has issued a report stating that, because the UK relies on imports for many components of its pharmaceuticals, “we are less self-sufficient and more vulnerable to supply shortages, and we ultimately lose high-value jobs and manufacturing know-how and skills.”
The report calls for the establishment of national “Centres of Excellence” that would develop manufacturing capabilities to ensure the supply of drugs, create an open-access facility with the capacity to manufacture patient-ready medicines, develop packaging and delivery-device technology, and support innovative manufacturing of advanced therapies. These initiatives are estimated to cost the UK government £140 million (approximately $179.5 million).
The report’s authors say that the development of the UK’s pharmaceuticals industry “can only happen if the various stakeholders work together and have a clear end goal, which has to be driven through by anchoring the UK as the country for all medicines innovation and manufacturing investment.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.